UnitedHealth Group's analyst fair value estimate has risen from $424.23 to $475.23, a 12% increase driven by Q2 earnings, Medicare Advantage and Optum Health updates, and refreshed 2026 earnings models. Several large firms raised price targets, with Wells Fargo moving from $485 to $526, Morgan Stanley from $468 to $529, and BofA from $475 to $512, citing better Medical Loss Ratio performance and Optum Health margin recovery. Revenue growth assumptions shifted from 3.12% to 3.47%, net profit margin from 4.43% to 4.71%, and future P/E multiple from 21.81x to 22.52x, while the discount rate remained near 7.11%. Bearish analysts flagged higher commercial costs and structural risks at Optum Health and Optum Insight, though near-term earnings risk is seen as more balanced.
UnitedHealth Group IncorporatedAnalyst fair value estimate and price targets raised after Q2 earnings, Medicare Advantage and Optum Health updates, and refreshed 2026 models.
